CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 35 enrolled
Drug / intervention
zoledronic aciddrug
Likely dose
zoledronic acid 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00361595
NCT00361595N/ACompleted
CompareCT.gov

Open Label Proof of Concept Study of IV Zoledronic Acid (ZA) 5 mg After Forteo in Postmenopausal Women

The Cleveland Clinic·interventional·Posted Aug 8, 2006·Updated Apr 21, 2017

In Brief

A clinical study evaluating zoledronic acid for Osteoporosis. Completed, enrolled 35 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the adequacy of zoledronic acid in maintaining bone mass after two years of treatment with Forteo, in postmenopausal women.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis
CountriesUnited States
CollaboratorsNovartis Pharmaceuticals

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 8, 2006
Enrollment StartAug 1, 2006
Primary CompletionApr 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 19.9 years ago

Interventions

zoledronic aciddrug

5 mg zoledronic acid administered in a single 15 minute IV